Cartherics Secures European Patent for Multiple Candidates

Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd, a biotechnology company specializing in the development of immune cell therapies for cancer treatment, has announced the receipt of its second European Patent. This patent, part of the international patent filing WO2017088012, strengthens Cartherics' hold on its innovative technology portfolio.

The newly granted European Patent No. 3708587 B1, titled 'Genetically Modified Cells and Uses Thereof,' secures the Company's proprietary technologies, particularly focusing on stem cells modified with Cartherics’ chimeric antigen receptor (CAR) targeting tumour-associated glycoprotein-72 (TAG-72). Moreover, it provides patent protection for allogeneic immune cell products derived from these genetically altered stem cells.

TAG-72 is prominently expressed in various adenocarcinomas such as ovarian and gastric cancers. The issuance of this patent is a significant stride in developing new treatments for such cancers, further augmenting Cartherics' extensive intellectual property collection.

Cartherics' primary therapeutic focus is on relapsed or refractory ovarian cancer, where more than 90% of tumors express TAG-72. By targeting these tumors with pioneering cellular immunotherapies, Cartherics aims to meet the urgent demand for innovative treatment options for these patients.

Commenting on this milestone, Cartherics’ CEO, Prof. Alan Trounson AO, stated: "Cartherics has made significant investments to ensure comprehensive patent protection for various facets of its technological platform. This European patent fortifies the network of patents that support the development and commercialization of the Company’s products, especially our lead product, CTH-401."

About Cartherics
Cartherics is a private biotechnology company located in Melbourne, Australia, dedicated to enhancing the immune system’s ability to combat cancer. The company is focused on developing cell-based immunotherapies, boasting a portfolio that includes CAR-T and CAR-NK cell products. Cartherics’ allogeneic cell platform is derived from induced pluripotent stem cells (iPSCs) obtained from donated cord blood, which can be differentiated into natural killer (NK) cells, T cells, and other immune cells. These iPSCs are genetically modified at specific genomic sites to enhance the functionality of the resulting NK and other immune cells. The Company’s flagship product, CTH-401, is a CAR-NK cell therapy designed to target TAG-72, a validated tumor marker, and includes the deletion of two genes linked to immunosuppression.

This patent not only fortifies Cartherics' position in the competitive field of cancer immunotherapy but also represents a leap forward in providing patients with advanced treatment options. The Company continues to innovate and expand its reach in the biotechnology landscape, driven by its commitment to harnessing the power of the immune system to fight cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!